{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:26Z","timestamp":1740144086130,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Clinical Research Fund, UZ Leuven"},{"name":"Flanders Research Foundation","award":["1843418N"],"award-info":[{"award-number":["1843418N"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40262-023-01344-1","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T16:03:21Z","timestamp":1705593801000},"page":"395-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug\u2013Drug Interactions"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5195-1891","authenticated-orcid":false,"given":"Lorenz","family":"Van der Linden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vanassche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Van Aelst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"issue":"11","key":"1344_CR1","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s40262-023-01298-4","volume":"62","author":"C Grange","year":"2023","unstructured":"Grange C, Rioufol C, Souquet PJ, Assaad S. Anti-coagulant treatment of cancer-associated thrombosis in frail patients: impact of frailties on the management of drug-drug interactions. Clin Pharmacokinet. 2023;62(11):1523\u201331.","journal-title":"Clin Pharmacokinet"},{"issue":"9868","key":"1344_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752\u201362.","journal-title":"Lancet"},{"issue":"12","key":"1344_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015656","volume":"9","author":"PL Lutsey","year":"2020","unstructured":"Lutsey PL, Windham BG, Misialek JR, Cushman M, Kucharska-Newton A, Basu S, et al. Long-term association of venous thromboembolism with frailty, physical functioning, and quality of life: the atherosclerosis risk in communities study. J Am Heart Assoc. 2020;9(12): e015656.","journal-title":"J Am Heart Assoc"},{"issue":"Suppl A","key":"1344_CR4","doi-asserted-by":"publisher","first-page":"A32","DOI":"10.1093\/eurheartj\/suab153","volume":"24","author":"L Van der Linden","year":"2022","unstructured":"Van der Linden L, Hias J, Vanassche T. The value and limitations of new oral anticoagulant plasma level assessments. Eur Heart J Suppl. 2022;24(Suppl A):A32\u201341.","journal-title":"Eur Heart J Suppl."},{"issue":"8","key":"1344_CR5","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/bcp.15785","volume":"89","author":"L Van der Linden","year":"2023","unstructured":"Van der Linden L, Vanassche T, Van Cutsem E, Van Aelst L, Verhamme P. Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis. Br J Clin Pharmacol. 2023;89(8):2369\u201376.","journal-title":"Br J Clin Pharmacol"},{"key":"1344_CR6","unstructured":"United States Federal Drug Administration. Drug Development and Drug Interactions. Table of Substrates, Inhibitors and Inducers. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed 22 Oct 2023."},{"key":"1344_CR7","unstructured":"European Medicines Agency. Investigation of drug interactions\u2014scientific guideline. https:\/\/www.ema.europa.eu\/en\/investigation-drug-interactions-scientific-guideline. Accessed 22 Oct 2023."},{"issue":"7","key":"1344_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31(7):815\u201332.","journal-title":"Drug Metab Dispos"},{"key":"1344_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","volume":"148","author":"M Verso","year":"2021","unstructured":"Verso M, Munoz A, Bauersachs R, Huisman MV, Mandala M, Vescovo G, et al. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer. 2021;148:371\u201381.","journal-title":"Eur J Cancer"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01344-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01344-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01344-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T11:31:07Z","timestamp":1710934267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01344-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1344"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01344-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"21 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lorenz Van der Linden reports grants from Daiichi Sankyo and Pfizer and has received fees from Amgen, Bayer, BMS\/Pfizer, Daiichi Sankyo, Sanofi Aventis and Servier. Thomas Vanassche reports fees for consultancy services and\/or participation in speakers' bureaus or advisory boards from BMS\/Pfizer, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Sanofi Aventis, and Servier. Peter Verhamme is co-holder of the Bayer Chair in Cardiovascular Medicine at the University of Leuven. He has received consulting fees from Bayer, Daiichi Sankyo, Portola, and Anthos Pharmaceuticals, and honoraria from Bayer, Daiichi Sankyo, BMS, Pfizer, Boehringer, and Leo Pharma. Lucas Van Aelst has no conflicts of interest to declare in relation to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"LVDL has received funding from the Clinical Research Fund of the University Hospitals Leuven (Leuven, Belgium). TV is holder of a senior clinical research fellowship from the Flanders Research Foundation (FWO;1843418N).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LVDL provided the first draft. All authors evaluated and approved the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable as no data were generated for this letter.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}]}}